HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BFE1224

Prodrug of antifungal Ravuconazole

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Pharmaceutical Preparations
- Prodrugs: 8091
  - BFE1224: 2
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - BFE1224: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - BFE1224: 2
    - Thiazoles: 392
      - BFE1224: 2

Experts

1.	Ishii, Yasuyuki: 1 article (01/2018)
2.	Ito, Yuko: 1 article (01/2018)
3.	Matsuki, Shunji: 1 article (01/2018)
4.	Ogawa, Osamu: 1 article (01/2018)
5.	Sanpei, Kasumi: 1 article (01/2018)
6.	Schuck, Edgar L: 1 article (01/2018)
7.	Takeda, Kenji: 1 article (01/2018)
8.	Uemura, Naoto: 1 article (01/2018)
9.	Yamaguchi, Hideyo: 1 article (01/2016)

Related Diseases

1.	Onychomycosis (Tinea Unguium) 01/01/2016 - "Given its clinical usefulness, BFE1224 may become a valuable addition to the current armamentarium for the treatment of onychomycosis." 01/01/2016 - " review aims to summarize our current status of knowledge and information on ravuconazole and its prodrugs, particularly BFE1224, as the potential oral treatment option for onychomycosis. " 01/01/2016 - " and its prodrugs are promising new drug candidates for oral therapy of onychomycosis, among which a water-soluble prodrug, mono-lysine phosphoester derivative (E1224 or BFE1224) is in the most advanced stage of clinical development; a Phase II dose-finding study has been successfully completed and Phase III comparative studies are in progress in Japan.This" 01/01/2018 - "BFE1224, prodrug of ravuconazole, is a novel, once-daily, oral, triazole antifungal drug, and currently in development for the treatment of onychomycosis. "
2.	Breast Neoplasms (Breast Cancer) 01/01/2018 - "The clinical DDIs of BFE1224 were mild for CYP3A and minor for other major CYPs (CYP1A2/2C8/2C9/2C19/2D6) as well as those of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1, and OATP1B3."

Related Drugs and Biologics

1.	Prodrugs
2.	Lysine (L-Lysine)
3.	ER 30346 (ravuconazole)
4.	Cytochrome P-450 CYP3A
5.	Member 1 Subfamily B ATP Binding Cassette Transporter
6.	Cytochrome P-450 CYP1A2 (CYP1A2)
7.	Triazoles
8.	Proteins (Proteins, Gene)
9.	Peptides (Polypeptides)
10.	Anions

Related Therapies and Procedures

1.	Therapeutics